^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

tumor lysate particle loaded dendritic cell vaccine (TL-YCWP-DC)

i
Other names: TL-YCWP-DC, TL+YCWP+DC, TLPLDC
Associations
Trials
Company:
Orbis Health Solutions
Drug class:
Immunostimulant
Related drugs:
Associations
Trials
8ms
Enrollment change • Checkpoint inhibition • Metastases
|
tumor lysate particle loaded dendritic cell vaccine (TL-YCWP-DC)
over1year
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis. (PubMed, J Immunother Cancer)
The TLPO and TLPLDC (without G-CSF) vaccines were associated with improved DFS and OS in this clinical trial. Given production and manufacturing advantages, the efficacy of the TLPO vaccine will be confirmed in a phase 3 trial.
Clinical • P2b data • Journal
|
tumor lysate particle loaded dendritic cell vaccine (TL-YCWP-DC)
over4years
[VIRTUAL] Impact of disease-free interval on recurrence in high-risk melanoma patients in a phase IIb trial of the tumor lysate particle loaded dendritic cell (TLPLDC) vaccine (AACR-II 2020)
The TLPLDC vaccine improved overall survival in patients with DFI >3 months prior to recurrence. These patients have more indolent disease biology and a less immunosuppressive tumor microenvironment, where monotherapy with a cancer vaccine is thought to be more effective. Further study is required to identify patients at initial presentation who are more likely to benefit from the TLPLDC vaccine.
Clinical • P2b data • IO biomarker
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
tumor lysate particle loaded dendritic cell vaccine (TL-YCWP-DC)